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equivalent slab phantom (PTW RW3). The Starcheck data 
acquisitions were done with the Multicheck software with 
only 100-200 MU and data analysis was handled by the 
MEPHYSTO software. Reference profiles measured in water 
were compared with profiles obtained with 2D array and 
Gafchromic films using the 2%/2mm gamma-index criterion. 
Output factor measurements were carried out for the central 
chamber of the array using its absolute dose value, and the 
results compared with the reference values. 
 
Results: Comparison between dose profiles obtained with 
Starcheck 2-Array, chamber, diode and Gafchromic film 
showed a good agreement and they satisfied gamma analysis 
(2%/2mm) for almost all the nominal energies and 
collimators. The high spatial resolution of Starcheck allows 
accurate evaluation of penumbra, symmetry, flatness and 
field size and the results showed dosimetric differences less 
than 1%, 1mm for all the energies in the reference collimator 
(10 cm). The absolute dose difference at the Zref (IAEA398) 
between central chamber of 2D-array and Advanced Markus 
was in the order of 1% for 6 and 9 MeV and was almost 1.5% 
for 9 MeV. Furthermore, the difference between output 
factor obtained with the 2D-array and other dosimeters was 
in the order of 2% for all collimators in different energies 
except for the smallest collimator (4cm) where the output 
factor deviated more than 3% from the other results. 
However, the results for beveled collimators were not 
acceptable due to angular response variation of chambers. 
 
 
 
Fig.1. Starcheck 2D array (a), data analyze with Multicheck 
software (b), crossplane profiles comparison: Starcheck and 
diode (c), Starcheck and EBT3 (d)  
 
Conclusion: The high spatial resolution, very small detector 
size and specific arrangement of this 2D array can be really 
suitable for dosimetry in IOERT. Additionally, it can reduce 
setup time and dose consumption more than 30% for 
frequently QC procedure. 
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Purpose or Objective: The IORT dedicated Treatment 
planning system (CSRAD+ ), already validated on simple 
geometries, has been used to perform calculation on patient-
like geometries and to compare the measured and the 
calculated dose distribution in a clinical configuration. In this 
study, sarcoma cancer patients have been considered. In 
sarcoma IORT treatments, the air gap between target and 
applicator and the extended dimensions are critical 
parameters that must be fully taken into account. The TPS 
and MC calculations are mandatory for documenting the dose 
delivery in order to potentially improve the treatment 
technique and to better evaluate dose effect correlation.  
 
Material and Methods: Twenty six patients with sarcoma 
cancer have been treated using NOVAC 7 with an energy from 
7 to 9 MeV, an applicator diameter from 40 to 100 mm, 
delivering a dose from 10 to 16 Gy. In vivo dosimetric data 
collected during IORT using Gaf films, have been used as the 
gold standard for testing the accuracy of the algorithms 
implemented in the TPS. CT images of five representative 
patients have been used to reproduce the surgery room 
scenario, using the collected data and taking into account 
tissue removal during the surgery procedure. Then, the CT 
images were imported in the TPS and used in order to 
perform an accurate dose calculation. The dose distribution 
have been compared with the in vivo dosimetry in order to 
perform a sensitivity analysis.  
 
Results: The TPS algorithms including the inhomogeneity 
correction have been investigated considering the clinical 
scenarios. The algorithm including the inhomogeneity 
correction allows the best agreement between the in-vivo 
dosimetry results and calculated dose, for mobile IORT 
accelerator. CSRAD+ permits to make a virtual docking, to 
delineate the target ROI, and to evaluate the dose 
distribution and the dose volume histogram. The sensitivity 
analysis revealed potential setup uncertainties (up to 80%) 
due to the manually performed alignment procedure in the 
surgical room and inaccuracy on target thickness when blood 
and air are present during the docking. 
  
 
 
Conclusion: The developed CSRAD+ shows a good agreement 
with experimental data and could replace the time 
consuming MC absolute dose calculation, becoming a 
potential on-line aid for physician and physicist in the 
surgical room. The CSRAD+ could represent a training tool for 
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IORT staff and could provide a provisional plan that includes 
also DVH and MU calculation.  
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Purpose or Objective: Monte Carlo (MC) recalculation of 
spot-scanning proton therapy treatment plans can provide an 
independent verification of monitor units required for 
delivery, and reduce the time treatment rooms need to be 
reserved for patient specific QA. We describe the 
development of such a MC verification system for a clinical 
facility. 
 
Material and Methods: Realistic clinical beam models were 
developed by matching simulations (using GATE/GEANT4) to 
measurements made in a clinical beamline. They consist of a 
tuned physics list, a lookup table relating each of the 115 
nominal beam energies to a tuned spot energy (mean and 
standard deviation) and phase space parameters which allow 
spot sizes to be properly modeled for any combination of 
energy and nozzle extension. For all beam energies 
simulations accurately reproduce both integral depth dose 
profiles (>97% of data-points pass a local gamma analysis at 
2%/2mm) and lateral profiles measured in air and in solid 
water (with a 0.2 mm maximum difference). The model was 
further validated against a series of simple test plans which 
were optimized in the clinical Treatment Planning System 
(TPS) to produce uniform dose volumes at various depths in 
water.The automated MC system can process, simulate and 
analyse treatment plans without user input once it receives 
the TPS files. 
 
Results: 
 
 
 
The system was tested for a three field (11k spot) base of 
skull treatment plan computed in a patient CT dataset. 
Simulations were split into 40 calculations over a 10 quad-
core CPU cluster, requiring <30 minutes to achieve dosimetric 
uncertainties (within the 90% isodose volume) of <1%. The 
figure demonstrates the broad agreement between the TPS 
(left) and the MC simulation (right). The local gamma pass 
rate between the two (bottom) is 97% at 4%/4mm (green 
voxels pass, red / blue voxels fail). This should be 
interpreted in the context of this being a highly 
inhomogeneous target site: Differences occurred only in 
heterogeneous regions where the TPS’s analytical dose 
calculation would be expected to model dose deposition less 
accurately than MC systems. For example, the MC simulations 
predict a lower dose around the sinus air cavities than the 
TPS. 
 
Conclusion: We have demonstrated that the MC verification 
system can accurately reproduce the dose distribution 
predicted by a clinical TPS. Further validation work is 
ongoing using a variety of plans and phantom measurements. 
Once clinically commissioned, the system can be used as an 
independent dose checker, reducing on-set verification time. 
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Purpose or Objective: To establish the workflow & 
methodology and to perform an experimental validation of 
treatment plan conversion from Tomotherapy HD machine 
(Accuray) using dynamic jaws to a True Beam (Varian) Linac. 
For this purpose, the RayStation (RS) TPS using fallback 
planning (RFP) is currently tested. An end-to-end set of 
phantom configurations of increasing complexity are 
presented. The ultimate goal is to validate this process in 
order to minimize the impact of machine downtime on 
patient treatments. 
 
Material and Methods: Four phantom based treatment plans 
were generated in the Tomotherapy Planning Station. These 
plans were mimicked with RFP for the TrueBeam using X6-FFF 
dual-arc VMAT. The first three cases planned on the Cheese 
Phantom (Std. Imaging) consisted of 1 to 4 target dose levels 
and 3 OARs, using heterogeneous inserts for the last one. The 
4th case was an integrated boost H&N treatment with 3 
target dose levels planned on an anthropomorphic phantom 
(H&N, IBA). Original Helical Tomotherapy (HT) and RS 
fallback plans were delivered respectively on each machine. 
Ion chamber (A1SL, Std. Imaging) and Gafchromic EBT3 (ISP) 
films were used to measure absolute and planar doses. First, 
for both machines beam delivery vs. treatment plan was 
evaluated as a baseline for absolute dose, gamma (γ) passing 
rate (criteria 3%/3mm) and overall uncertainties. Secondly, 
in order to ensure that the difference between the two 
calculated dose distributions (TPS_TOMO / TPS_RAYSTATION) 
matched the differences between the two measured film 
dose distributions (Film_TOMO / Film_RAYSTATION), a γ 
difference (5%/5mm) was performed. 
 
 
 
Results: First, gamma evaluation was (99.1±0.6)% for HT and 
(99.5±0.4)% for RS fallback plans while absolute dose 
differences between calculations and ion chamber 
measurements were respectively 0.9% for HT and -0.7% for RS 
on average for all end-to-end tests. Secondly, average γ 
difference between calculated doses TPS_TOMO / 
